$30 Million Verrica Pharmaceuticsls Follow-on Offering Bookrunner, March 2021 Related Topics BiotechnologyEquity Capital MarketsHealth CareNorth AmericaPharmaceuticals – SpecialtyVerrica Pharmaceuticsls